Clinical Trial

A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)

Study acronym: STIPS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-30
Trial Details
NCT Number NCT07704840
Lead Sponsor Alberto Esquenazi
Collaborators: Bristol-Myers Squibb
Conditions Post-Stroke Spasticity
Enrollment 42 participants
Start Date 2026-07
Primary Completion 2027-06 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-29